ClinicalTrials.gg
TerminatedNCT02109016Updated Jul 29, 2019

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

A Phase 2 interventional study of Lucitanib in Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and NSCLC, sponsored by Clovis Oncology, Inc.. Terminated at 19 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-29.

Sponsored by Clovis Oncology, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
2,367th of 2,995
18 · median 56
Started
2014
with 95 others
Phase 2
1,078 of 3,368
119 open now
Registered
1,415th of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 2,367th largest by enrollment of the 2,995 interventional ones that give a count, is one of 96 that started in 2014, is one of 1,078 in phase 2, and was the 1,415th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with advanced/metastatic lung cancer and fibroblast growth factor (FGF), vascular endothelial growth factor receptor (VEGF), or platelet derived growth factor (PDGF) related genetic alterations.

Read the detailed description

Lucitanib is an oral inhibitor of the tyrosine kinase activity of FGFR 1-3, VEGFR 1-3, and PDGFR α/β. Lucitanib has demonstrated potent anti-tumor and anti-angiogenic activity in vitro proliferation assays and in vivo using human tumor xenograft models, with a trend for stronger efficacy in those with genomic aberrancies of FGF or PDGF. Abnormalities in the FGF, VEGF, and PDGF-related genes are observed across lung cancer histologies.

The first in human trial of lucitanib demonstrated that daily lucitanib is clinically active in patients with advanced solid tumors. Specifically, patients with FGFR1-amplification appeared to derive particular benefit from lucitanib.

Based on these results, this study is designed to explore the safety and anti-tumor activity of daily lucitanib in lung cancer patients with FGF, VEGF, and PDGF genetic alterations.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Squamous Non-Small Cell Lung Cancer
  • NSCLC
  • Small Cell Lung Cancer
  • SCLC
  • Lung Cancer
  • Advanced Lung Cancer
  • Metastatic Lung Cancer
  • Stage IV Lung Cancer

Keywords

  • FGFR1 amplification
  • FGF alteration
  • VEGF alteration
  • PDGF alteration
  • Tyrosine kinase inhibitor
  • VEGFR inhibitor
  • FGFR inhibitor
  • PDGFR inhibitor
  • VEGFR-FGFR inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced/ SCLC or NSCLC
  • Any of the following tumor tissue based genetic alterations: FGFR1, FGFR2, FGFR3, VEGFA, or PDGFRα amplification; Any FGFR1, FGFR2, or FGFR3 gene fusion; FGFR1, FGFR2, or FGFR3 activating mutation
  • Availability of tumor tissue sample suitable for the central confirmation of the genetic alteration and exploratory analyses
  • (ECOG) of 0 or 1
  • per 1.1
  • Documented radiographic disease progression following at least one in the advanced/metastatic setting

Exclusion criteria

Exclusion Criteria:

  • Tumors that are invading a major vessel; NSCLC tumors abutting to a major vessel
  • Uncontrolled hypertension, defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with optimized anti-hypertensive therapy
  • Uncontrolled hypothyroidism defined as serum thyroid stimulating hormone (TSH) higher than 5 mIU/mL while receiving appropriate thyroid hormone therapy
  • Symptomatic and/or untreated central nervous system
  • Presence of another active cancer
  • Ongoing adverse events from surgery or prior anti-cancer therapies, including radiation, targeted, or cytotoxic therapies
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Lucitanib

    Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.

    Drug: Lucitanib

Interventions

  • Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity. Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Proportion of patients in whom a confirmed Complete Response (CR) or a confirmed Partial Response (PR), as best overall response according to RECIST criteria, is observed.

    Time frame: Screening, every 8 weeks; up to 2 years

Secondary outcomes

  1. Clinical Benefit Rate (CBR)

    Proportion of patients in whom a confirmed CR or confirmed PR or a prolonged Stable Disease (SD) (≥ 6 months), as best overall response according to RECIST, is observed

    Time frame: Screening, every 8 weeks; up to 2 years

  2. Progression-Free Survival (PFS)

    Time from the date of first drug intake until the date of progression or death for any cause

    Time frame: Screening, every 8 weeks; up to 2 years

  3. Duration of response (DOR)

    For responders (i.e. patients with best overall response CR or PR), the interval from the time of first documentation of response to the date of progression or death for any cause

    Time frame: Screening, every 8 weeks; up to 2 years

  4. Duration of clinical benefit

    For responders and patients with SD as best overall response, time from the first drug intake until the date of progression or death for any cause

    Time frame: Screening, every 8 weeks; up to 2 years

  5. Overall Survival (OS)

    From the date of first drug intake to the date of death for any cause

    Time frame: Continuously; up to 2 years

  6. Tumor growth kinetics

    Will be evaluated using the following criteria: tumor size; tumor volume; tumor growth

    Time frame: Screening, every 8 weeks; up to 2 years

  7. Incidence of adverse events (AEs), clinical laboratory abnormalities, and dose modifications

    Time frame: Continuously; up to 2 years

  8. PK parameters of lucitanib

    Time frame: Cycle 1 Day 14 and 28, Cycle 2 Day 28, Cycle 3 Day 28

  9. Pharmacogenomic analysis of inter-patients variation in gene encoding ADME involved proteins

    Time frame: Cycle 1 Day 1

  10. Pharmacodynamic (PD) evaluation of lucitanib profile

    Soluble growth factors and other biomarkers, including circulating tumor DNA

    Time frame: Cycle 1 Day 1 and 14, End of Study

07

Study locations

19 sites
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Associates in Oncology and Hematology
    Rockville, Maryland 20850, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • CHU Caen, Hôpital de la Côte de Nacre
    Caen, 14033, France
  • CHRU Lille, Hôpital Albert Calmette
    Lille, 59037, France
  • Hôpital Nord
    Marseille, 13915, France
  • Institut Gustave-Roussy
    Villejuif, 94805, France
  • Universität Duisburg-Essen
    Essen, 45147, Germany
  • Hospital Grosshansdorf
    Grosshansdorf, 22927, Germany
  • Pius Hospital Oldenburg
    Oldenburg, 26121, Germany
  • Ospedale San Raffaele
    Milano, 20132, Italy
  • Fondazione IRCCS Istituto Nazionale Tumori
    Milano, 20133, Italy
  • AOU San Luigi Gonzaga
    Orbassano, 10043, Italy
  • Ospedale S. Maria della Misericordia
    Perugia, 06156, Italy
  • Hospital Universitari Vall d'Hebrón
    Barcelona, Cataluña 8035, Spain
08

References and documents

Publications

  • Liao M, Zhou J, Wride K, Lepley D, Cameron T, Sale M, Xiao J. Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer. Eur J Drug Metab Pharmacokinet. 2022 Sep;47(5):711-723. doi: 10.1007/s13318-022-00773-w. Epub 2022 Jul 18. PubMed 35844029 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Apr 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2014
First posted
Apr 9, 2014
Start
Apr 2014
Primary completionActual
Apr 1, 2016
CompletionActual
Sep 2016
Results delay requested
Jul 21, 2017
Last update
Jul 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02109016
Lead sponsor
Clovis Oncology, Inc.
Responsible party
Sponsor
First posted
Apr 9, 2014
Start date
Apr 2014
Primary completion
Apr 1, 2016
Completion
Sep 2016
Last update
Jul 29, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: E-3810

Start the discussion